Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 23, 2009

PATH Malaria Vaccine Initiative Allies with VGX

  • The PATH Malaria Vaccine Initiative (MVI) agreed to evaluate VGX Pharmaceuticals’ (VGX) SynCon™ DNA vaccine development platform. Vaccine development and malaria experts from the University of Pennsylvania School of Medicine will work with the company.

    VGX will design and test DNA vaccine candidates using target antigens from Plasmodium species. Delivery will be done intradermally using its Cellectra® constant current electroporation device.

    Cellectra is also being developed for the delivery of DNA vaccine and therapeutic candidates via intramuscular routes. Furthest along in VCX’ pipeline are Pennvax™-B as a preventive and therapeutic vaccine for HIV infection and VGX-3100 as a therapeutic vaccine for cervical cancer. Both are in Phase I testing.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »